Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine for Cortical Hyperexcitability in SALS
NCT02781454Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mexiletine in amyotrophic lateral sclerosis (ALS), sponsored by University of Washington. Started Oct 2016; status: completed.
02
Drugs
mexiletine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02781454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781454.